美国肝性脑病患者利福昔明使用和亚专科转诊中的种族和民族差异
该研究基于2011-2019年美国Medicare 20%随机样本,纳入29,095例接受门诊乳果糖治疗的肝硬化肝性脑病患者,分析种族和民族与利福昔明处方及消化科转诊的关联。相比白人,黑人患者接受利福昔明处方的可能性最低(sHR 0.70;95%CI 0.65-0.76),黑人和西班牙裔患者利福昔明暴露剂量更少、自付费用更高、转诊至消化科的可能性更低。
要点
- 黑人患者接受利福昔明处方的可能性低于白人患者(sHR 0.70;95%CI 0.65-0.76)。
- 黑人和西班牙裔患者利福昔明暴露剂量少于白人患者(暴露时长比分别为0.90和0.88)。
- 黑人和西班牙裔患者转诊至消化科的可能性最低,自付费用更高。
核心结论
- 在全国肝性脑病患者队列中,利福昔明使用存在显著的种族和民族差异。
- 作者认为,解决利福昔明费用和消化科可及性问题可能有助于改善这些差异。
研究设计与样本
- 研究为回顾性队列分析,使用2011-2019年美国Medicare参保者20%随机样本。
- 纳入肝硬化合并肝性脑病、接受门诊乳果糖治疗且有Part D处方覆盖的患者,共29,095例,其中13,272例被处方利福昔明。
- 采用Fine-Gray竞争风险模型计算亚分布风险比(sHR),采用gamma hurdle模型计算暴露时长比。
主要发现
- 相比白人患者,黑人患者接受利福昔明处方的可能性最低(sHR 0.70;95%CI 0.65-0.76)。
- 亚洲和西班牙裔患者接受利福昔明处方的可能性也低于白人患者。
- 黑人患者利福昔明暴露剂量少于白人患者(暴露时长比0.90;95%CI 0.82-0.98),西班牙裔患者也少于白人患者(0.88;95%CI 0.80-0.98)。
- 黑人和西班牙裔患者每人年利福昔明自付费用高于白人患者。
- 黑人和西班牙裔患者转诊至消化科的可能性最低。
关键数值与推荐
- 黑人患者接受利福昔明处方的sHR为0.70(95%CI 0.65-0.76),对照为白人患者。
- 黑人患者利福昔明暴露时长比为0.90(95%CI 0.82-0.98),西班牙裔患者为0.88(95%CI 0.80-0.98),对照为白人患者。
- 自付药物支出与填写利福昔明处方的几率降低相关。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Rifaximin use in combination with lactulose is associated with a decreased risk of overt hepatic encephalopathy (HE). We sought to determine whether race and ethnicity were associated with rifaximin prescriptions. METHODS: We examined data for a 20% random sample of United States Medicare enrollees with cirrhosis and hepatic encephalopathy treated with outpatient lactulose and Part D prescription coverage from 2011-2019. Beginning at the time of first diagnosis, we evaluated time to first prescription of rifaximin accounting for competing risks (Fine-Gray, yielding subdistribution hazard ratios [sHRs]) and cumulative rifaximin exposure using a gamma hurdle model (yielding exposure length ratios). We aimed to determine the association of race and ethnicity with each outcome, adjusting for demographics, clinical factors, and other features of clinical management. RESULTS: Overall, 29,095 patients were diagnosed with HE and treated with lactulose, of whom 13,272 were prescribed rifaximin. Compared to White patients, Black patients were least likely to receive any prescription for rifaximin (sHR 0.70; 95% CI 0.65-0.76). Asian and Hispanic patients were also less likely to receive rifaximin compared to White patients. Black patients also received fewer doses of rifaximin (exposure length ratio 0.90; 95% CI 0.82-0.98). Hispanic patients also received fewer doses (0.88; 95% CI 0.80-0.98). Out-of-pocket spending on rifaximin per person-year was higher for Black and Hispanic than White patients. Out-of-pocket medication spending was associated with reduced odds of filling a rifaximin prescription. Black and Hispanic patients were least likely to be referred to a gastroenterologist. CONCLUSION: In a national cohort of patients with HE, we observed stark racial and ethnic disparities in the use of rifaximin, an approved therapy for the improvement of HE-specific outcomes. Access to gastroenterologists and cost controls may reduce disparities. LAY SUMMARY: Hepatic encephalopathy is a serious problem that can affect people with cirrhosis. When someone develops hepatic encephalopathy, there are 2 main treatments. The first-line treatment is called lactulose. If episodes of hepatic encephalopathy happen on lactulose, another treatment called rifaximin is recommended. In this study, we found that compared to White patients, Black and Hispanic patients are less likely to be prescribed rifaximin, receive fewer rifaximin refills, spend more on rifaximin, and have less access to subspecialists who are familiar with rifaximin. We conclude that efforts to address the cost of rifaximin and access to gastroenterologists could help improve these disparities.
引用
- Tapper EB, Essien UR, Zhao Z, et al. Racial and ethnic disparities in rifaximin use and subspecialty referrals for patients with hepatic encephalopathy in the United States. J Hepatol. 2022. PMID: 35367057. doi:10.1016/j.jhep.2022.02.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。